THERAPEUTIC AREAS
CHRONIC SINUSITIS
Chronic rhinosinusitis (CRS) impacts approximately 12% of the general population, or around 900 million patients.
CHRONIC RHINITIS
Persistent moderate to severe rhinitis impacts approximately 19% of the general population, or around 1.4 billion patients.
20% of patients suffering from chronic sinusitis face treatment failure.
25% of patients suffering from Rhinitis face treatment failure.
OUR TECHNOLOGICAL PLATFORM
In chronic sinusitis and rhinitis, 20% to 25% of patients do not respond to drug treatment. There is a need for non surgical minimally invasive therapeutic alternatives. Dianosic develops an Active Resorbable Intranasal Scaffold (ARIS) technological platform with dedicated applications in chronic rhinitis (ARIS-R) and chronic sinusitis (ARIS-S). Those highly versatile, drug-eluting, long-term resorbable polymer solutions will transform the management of those debilitating diseases.
Long term resorbable solutions
6 months (ARIS-R)
12 months (ARIS-S)
Minimally invasive & easy to use
No prior surgery required
100% compliance
Implantable “in-office”
Quick return to home
Reduced budget impact (hospitals, insurers)